uniQure reports $308.5M net loss in FY2023; cash $617.9M; pipeline programs advancing

uniQure N.V.

2023-FY EPS reported -$6.47 revenue$15,843,000

Net loss $308.5M ($6.47 per share) vs $126.8M ($2.71) in FY2022; revenue $15.8M vs $106.5M.
Cash and investments $617.9M as of Dec 31, 2023; expects to fund operations into Q2 2027.
Strategic reorganization expected to deliver $180M in cost savings over three years.
FDA clearance received for IND applications for AMT-260 (mTLE) and AMT-191 (Fabry); enrollment in Phase I/II trials expected H1 2024.
Regulatory interactions for AMT-130 (Huntington's) approval pathway expected in 2024; interim data update in mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

uniQure N.V. reported fourth quarter and full year 2023 results: revenue $15.8 million.

Period: fourth quarter and full year 2023
Revenue: $15.8 million
Result: reported results

Exact text from the filing

Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027. Revenues: Revenue for the year ended December 31, 2023 was $15.8 million, compared to $106.5 million in the same period in 2022. Revenues in 2022 included $100.0 million of license revenue related to the U.S. first sale milestone payment of HEMGENIX ®

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-24-028484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.